CA-C3-AI
16.2.2021 22:29:13 CET | Business Wire | Press release
C3 AI (NYSE:AI), a leading enterprise AI software provider, today announced the release of major enhancements to its enterprise AI application development platform and AI applications designed to further accelerate digital transformation. Over the past decade, C3 AI has invested continuously in the C3 AI® Suite, its open, secure, and multi-cloud enterprise AI platform that leverages a model-driven architecture, enabling end-to-end enterprise AI including data integration, model development, MLOps, application development, and model governance and maintenance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006166/en/
The latest release – Version 7.17 – provides new capabilities to track and manage full lineage from data sources to application entities. In addition, the latest release includes new composable machine learning (ML) pipelines for data scientists; enhancements to C3 AI CRM, C3 AI Anti-Money Laundering, C3 AI Energy Management, C3 AI Production Schedule Optimization, and C3 AI Reliability applications; and a new enterprise AI application for the oil and gas industry, C3 AI Well Development Optimization.
“Today’s release introduces even more market-leading features for developers, data scientists, and data engineers, while bringing unparalleled speed to the development of enterprise AI applications,” said C3 AI President and Chief Product Officer Houman Behzadi. “We continue to invest significantly in our enterprise AI platform, wide range of developer tools, and configurable enterprise AI applications to enable a richer and more cohesive developer and user experience to accelerate AI adoption.”
The latest platform enhancements and features available with the C3 AI Suite include:
- Comprehensive data, feature, and model lineage: Improvements to enterprise AI application development tools include a new comprehensive data, feature, and model lineage component that enables developers and end users to understand the lineage of their application and AI/ML results.
- Enhanced time series feature generation: The latest release significantly accelerates feature engineering and model development. Enhancements enable faster feature parameterization, more comprehensive statistical transformations, and improved feature selection for use in C3 AI ML Pipelines.
- New composable ML pipelines: Expanding the ever-growing library of C3 AI ML Pipelines, the latest release includes four new pipelines to accelerate model development, including a deep learning pipe for forecasting and a linear quantile regression pipe for probabilistic predictions. C3 AI ML Pipelines also deliver improved model interpretability support with the addition of SHAP (Shapley Additive Explanations) to the available explainability frameworks.
- Multi-cloud Kubernetes service: As part of the ongoing Kubernetes/OpenShift standardization, the latest release supports the Kubernetes service on all clouds.
- New prebuilt data connectors: Performance and scalability improvements to C3 AI’s Virtual Data Lake framework include connectors to Snowflake, Spark/Databricks, S3, Microsoft Power BI, Azure Data Lake, and Microsoft Dynamics 365 – further expanding the library of prebuilt data connectors on the C3 AI Suite. The new connectors help accelerate data integration and allow engineers to create a virtual data image or ingest data directly into the C3 AI Suite.
- Enhancements to enterprise object models: New additions and enhancements to C3 AI’s suite of prebuilt enterprise object models further accelerate development of AI applications. Cross-industry object models provide functional capabilities, including energy management, equipment and process reliability, fraud detection, inventory optimization, and manufacturing yield optimization. In addition, C3 AI also offers industry-specific object models for manufacturing, financial services, oil and gas, utilities, and defense.
C3 AI also continues to invest in its growing portfolio of enterprise AI applications. Notable enhancements include:
- C3 AI CRM delivers a new AI-based precision revenue forecasting and opportunity scoring feature leveraging both data in traditional CRM systems and external feeds (e.g., financial data, news, commodity prices).
- C3 AI Reliability enhancements include a new module – C3 AI Diagram Parsing – to automatically generate digital twins and object models from piping and instrumentation diagrams (P&IDs). C3 AI Diagram Parsing uses machine vision and natural language processing to parse P&IDs to generate machine-readable asset hierarchies and sensor-to-asset mappings.
- C3 AI Inventory Optimization enhancements include what-if scenario modeling capabilities for inventory analysts to account for the ever-changing dynamics of globally distributed supply chains and optimize for the best operating outcomes.
- C3 AI Production Schedule Optimization enhancements include a new user interface, enhancements to the object model, and additional composable ML pipelines. Modifications to the user interface enable end users to more easily generate, review, and act on AI-based demand forecasts and order line recommendations. The newly available demand planning and scheduling data models and ML pipelines help accelerate model development and deployment for data science teams.
- C3 AI Well Development Optimization is a new oil and gas application that optimizes upstream drilling costs and mitigates non-productive time risks such as stuck pipe, lost circulation, and drilling recovery. The application provides the foundational data model for AI-enabled well development applications, as well as for upstream oil and gas operators to plan and execute drilling operations.
For more information about this new release, please contact sales@c3.ai .
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
